S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Join Morningstar today. It's Free.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Neuralstem President And CEO To Present At The 2013 Rodman & Renshaw Annual Healthcare Conference ()|
|Neuralstem Reports Third Quarter Financial Results And Provides Business And Clinical Update (2013/11/12)|
|Neuralstem Cells Reverse Cognitive Defect In Brain-Irradiated Rats, University Of California Irvine Paper Shows ()|
|Neuralstem CEO To Present At Stem Cells & Regenerative Medicine Congress (2013/9/26)|
|University Of Michigan Health System Treats Its First Patients In Neuralstem's Phase II ALS Stem Cell Trial (2013/10/9)|
|Neuralstem Reports Second Quarter Financial Results And Provides Business And Clinical Update ()|
|Neuralstem To Raise $4 Million In Registered Direct Offering (2013/9/5)|
|First Patient Treated In Phase II Of Neuralstem ALS Stem Cell Trial (2013/9/10)|
|Dr. Eva Feldman, Principal Investigator, to Give Update on ALS Trial at American Neurological Association Meeting (2013/10/10)|
|StemCells, Inc. Acquires Seminal Neural Stem Cell Patent Portfolio (2013/10/29)|
Click above to view more mutual fund data and stats for cur - Neuralstem, Inc..